产品活性： PF-07104091 hydrate 是一种高效选择性的 CDK2/cyclin E1 和 GSK3β 抑制剂，其 Ki 分别为 1.16 和 537.81 nM。PF-07104091 hydrate ...

Initial clinical data from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader (MGD) MRT-6160 expected in Q1 2025Additional clinical ...

Zentalis Pharmaceuticals has won a U.S. Food and Drug Administration fast-track designation for its lead product candidate azenosertib for certain cancer patients with high levels of the Cyclin E1 ...

All rights reserved. Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP. A Charity, Not for Profit. Company Limited by Guarantee. Registered in England No.

In a large-animal model study, researchers have found that heart attack recovery is aided by injection of heart muscle cell spheroids derived from human induced pluripotent stem cells, or hiPSCs, that ...

In a large-animal model study, researchers have found that heart attack recovery is aided by injection of heart muscle cell ...

RVU-120 is under clinical development by Ryvu Therapeutics and currently in Phase II for Anemia. According to GlobalData, Phase II drugs for Anemia have a 53% phase transition success rate (PTSR) ...

Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Pancreatic Cancer.

Immedica Pharma AB to acquire Marinus Pharmaceuticals in a tender offer and merger, strengthening its global rare disease business.

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor ...